Additionally, the 36-month beta value for JAGX is 0.68. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAGX is 1.09M and currently, short sellers hold a 2.64% ratio of that float. The average trading volume of JAGX on June 25, 2025 was 142.18K shares.
JAGX) stock’s latest price update
Jaguar Health Inc (NASDAQ: JAGX) has experienced a rise in its stock price by 107283 compared to its previous closing price of 2.7. However, the company has seen a fall of -11.59% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-24 that Company’s CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) (“Jaguar” or “the Company”), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.
JAGX’s Market Performance
Jaguar Health Inc (JAGX) has seen a -11.59% fall in stock performance for the week, with a -32.67% decline in the past month and a -49.50% plunge in the past quarter. The volatility ratio for the week is 11.30%, and the volatility levels for the past 30 days are at 5.81% for JAGX. The simple moving average for the past 20 days is -18.57% for JAGX’s stock, with a -83.22% simple moving average for the past 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -50.28% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.25% of loss for the given period.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.78 for the present operating margin
- 0.82 for the gross margin
The net margin for Jaguar Health Inc stands at -3.45. The total capital return value is set at -1.38. Equity return is now at value -423.79, with -74.37 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.98 points at debt to capital in total, while cash flow to debt ratio is standing at -0.77. The debt to equity ratio resting at 46.19. The interest coverage ratio of the stock is -572.09.
Currently, EBITDA for the company is -36.66 million with net debt to EBITDA at -0.85. When we switch over and look at the enterprise to sales, we see a ratio of 3.17. The receivables turnover for the company is 9.41for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In conclusion, Jaguar Health Inc (JAGX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
